APOBEC3C-Mediated NF-κB Activation Promotes Malignant Progression of Gliomas

IF 3.1 4区医学 Q3 IMMUNOLOGY

Immunity, Inflammation and Disease Pub Date : 2025-07-24 DOI:10.1002/iid3.70224

Chao Zhang, Tao Yang, Yuhang Tang, Dong Yu, Shiqiang Hou, Ning Lin, Qun Li

{"title":"APOBEC3C-Mediated NF-κB Activation Promotes Malignant Progression of Gliomas","authors":"Chao Zhang, Tao Yang, Yuhang Tang, Dong Yu, Shiqiang Hou, Ning Lin, Qun Li","doi":"10.1002/iid3.70224","DOIUrl":null,"url":null,"abstract":"<div>\n \n \n <section>\n \n <h3> Objective</h3>\n \n <p>To analyze the clinicopathological features, immunological characteristics, and prognostic value of APOBEC3C in gliomas, and to verify the specific mechanism by which it mediates the malignant progression of gliomas.</p>\n </section>\n \n <section>\n \n <h3> Methods</h3>\n \n <p>mRNA-seq data from 693 glioma patients in the CGGA database and 697 glioma patients in the TCGA were analyzed, respectively. In addition, single-cell sequencing data were obtained from the CGGA database. Bioinformatics methods were applied to reveal the possible mechanisms of APOBEC3C-mediated malignant progression of gliomas. Moreover, western blot, transwell, and cell-scratch assays were used to explore the potential mechanisms of APOBEC3C-mediated glioma invasion and migration.</p>\n </section>\n \n <section>\n \n <h3> Results</h3>\n \n <p>APOBEC3C was enriched in malignant glioma subtypes and was a potential biomarker for mesenchymal subtypes in glioma patients. It was closely associated with glioma inflammation and immunity. Additionally, APOBEC3C is a potential independent prognostic factor for glioma, and inhibition of APOBEC3C expression can suppress the EMT process in glioma cells through the NF-κB signaling pathway.</p>\n </section>\n \n <section>\n \n <h3> Conclusion</h3>\n \n <p>APOBEC3C is a potential biomarker for glioma patients. It is closely related to the clinicopathology of glioma and may be a potential immunotherapy target for glioma patients.</p>\n </section>\n </div>","PeriodicalId":13289,"journal":{"name":"Immunity, Inflammation and Disease","volume":"13 7","pages":""},"PeriodicalIF":3.1000,"publicationDate":"2025-07-24","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1002/iid3.70224","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Immunity, Inflammation and Disease","FirstCategoryId":"3","ListUrlMain":"https://onlinelibrary.wiley.com/doi/10.1002/iid3.70224","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q3","JCRName":"IMMUNOLOGY","Score":null,"Total":0}

引用次数: 0

Abstract

Objective

To analyze the clinicopathological features, immunological characteristics, and prognostic value of APOBEC3C in gliomas, and to verify the specific mechanism by which it mediates the malignant progression of gliomas.

Methods

mRNA-seq data from 693 glioma patients in the CGGA database and 697 glioma patients in the TCGA were analyzed, respectively. In addition, single-cell sequencing data were obtained from the CGGA database. Bioinformatics methods were applied to reveal the possible mechanisms of APOBEC3C-mediated malignant progression of gliomas. Moreover, western blot, transwell, and cell-scratch assays were used to explore the potential mechanisms of APOBEC3C-mediated glioma invasion and migration.

Results

APOBEC3C was enriched in malignant glioma subtypes and was a potential biomarker for mesenchymal subtypes in glioma patients. It was closely associated with glioma inflammation and immunity. Additionally, APOBEC3C is a potential independent prognostic factor for glioma, and inhibition of APOBEC3C expression can suppress the EMT process in glioma cells through the NF-κB signaling pathway.

Conclusion

APOBEC3C is a potential biomarker for glioma patients. It is closely related to the clinicopathology of glioma and may be a potential immunotherapy target for glioma patients.

Abstract Image

查看原文本刊更多论文

apobec3c介导的NF-κB活化促进胶质瘤的恶性进展

目的分析APOBEC3C在胶质瘤中的临床病理特征、免疫学特征及预后价值，验证其介导胶质瘤恶性进展的具体机制。方法对CGGA数据库中693例胶质瘤患者和TCGA数据库中697例胶质瘤患者的mRNA-seq数据进行分析。此外，从CGGA数据库中获得单细胞测序数据。应用生物信息学方法揭示apobec3c介导的胶质瘤恶性进展的可能机制。此外，western blot、transwell和细胞划痕实验被用于探索apobec3c介导的胶质瘤侵袭和迁移的潜在机制。结果APOBEC3C在恶性胶质瘤亚型中富集，是胶质瘤患者间充质亚型的潜在生物标志物。它与胶质瘤炎症和免疫密切相关。此外，APOBEC3C是胶质瘤潜在的独立预后因子，抑制APOBEC3C表达可通过NF-κB信号通路抑制胶质瘤细胞的EMT过程。结论APOBEC3C是胶质瘤患者潜在的生物标志物。它与胶质瘤的临床病理密切相关，可能是胶质瘤患者潜在的免疫治疗靶点。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Immunity, Inflammation and Disease Medicine-Immunology and Allergy

CiteScore

3.60

自引率

0.00%

发文量

146

审稿时长

8 weeks

期刊介绍： Immunity, Inflammation and Disease is a peer-reviewed, open access, interdisciplinary journal providing rapid publication of research across the broad field of immunology. Immunity, Inflammation and Disease gives rapid consideration to papers in all areas of clinical and basic research. The journal is indexed in Medline and the Science Citation Index Expanded (part of Web of Science), among others. It welcomes original work that enhances the understanding of immunology in areas including: • cellular and molecular immunology • clinical immunology • allergy • immunochemistry • immunogenetics • immune signalling • immune development • imaging • mathematical modelling • autoimmunity • transplantation immunology • cancer immunology